Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'hormone refractory' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 88 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Mitsiades, CS; Koutsilieris, M
      Molecular biology and cellular physiology of refractoriness to androgen ablation therapy in advanced prostate cancer

      EXPERT OPINION ON INVESTIGATIONAL DRUGS
    2. Eid, JE; Brunner, A; Cummings, KB; Weiss, RE; Goodin, S; Aisner, J; Todd, M; DiPaola, RS
      Effect of P-30 protein and tamoxifen on transforming growth factor-beta 1 in patients with rising prostate specific antigen

      UROLOGIC ONCOLOGY
    3. Ito, T; Yamamoto, S; Ohno, Y; Namiki, K; Aizawa, T; Akiyama, A; Tachibana, M
      Up-regulation of neuroendocrine differentiation in prostate cancer after androgen deprivation therapy, degree and androgen independence

      ONCOLOGY REPORTS
    4. Mousses, S; Wagner, U; Chen, YD; Kim, JW; Bubendorf, L; Bittner, M; Pretlow, T; Elkahloun, AG; Trepel, JB; Kallioniemi, OP
      Failure of hormone therapy in prostate cancer involves systematic restoration of androgen responsive genes and activation of rapamycin sensitive signaling

      ONCOGENE
    5. Kornblith, AB; Herndon, JE; Zuckerman, E; Godley, PA; Savarese, D; Vogelzang, NJ; Holland, JC
      The impact of docetaxel, estramustine, and low dose hydrocortisone on the quality of life of men with hormone refractory prostate cancer and their partners: A feasibility study

      ANNALS OF ONCOLOGY
    6. Caldiroli, M; Cova, V; Lovisolo, JA; Reali, L; Bono, AV
      Antiandrogen withdrawal in the treatment of hormone-relapsed prostate cancer: Single institutional experience

      EUROPEAN UROLOGY
    7. El Gedaily, A; Bubendorf, L; Willi, N; Fu, W; Richter, J; Moch, H; Mihatsch, MJ; Sauter, G; Gasser, TC
      Discovery of new DNA amplification loci in prostate cancer by comparative genomic hybridization

      PROSTATE
    8. Serretta, V; Rizzo, I; Contino, G; Pavone, C; Pomara, G; Melloni, D; Pavone-Macaluso, M
      PSA and second-line therapy of hormone refractory prostate carcinoma

      UROLOGIA INTERNATIONALIS
    9. Takezawa, Y; Nakata, S; Kobayashi, M; Kosaku, N; Fukabori, Y; Yamanaka, H
      Moderate dose diethylstilbestrol diphosphate therapy in hormone refractoryprostate cancer

      SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY
    10. Johansson, JE; Wersall, P; Brandberg, Y; Andersson, SO; Nordstrom, L
      Efficacy of epoetin beta on hemoglobin, quality of life, and transfusion needs in patients with anemia due to hormone-refractory prostate cancer - A randomized study

      SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY
    11. Nishimura, K; Nonomura, N; Ono, Y; Nozawa, M; Fukui, T; Harada, Y; Imazu, T; Takaha, N; Sugao, H; Miki, T; Okuyama, A
      Oral combination of cyclophosphamide, uracil plus tegafur and estramustinefor hormone-refractory prostate cancer

      ONCOLOGY
    12. Vainas, IG
      Octreotide in the management of hormone-refractory prostate cancer

      CHEMOTHERAPY
    13. Calvo, E; Cortes, J; Rodriguez, J; Sureda, M; Beltran, U; Rebollo, J; Martinez-Monge, R; Berian, JM; de Irala, J; Brugarolas, A
      Fixed higher dose schedule of suramin plus hydrocortisone in patients withhormone refractory prostate carcinoma - A multicenter phase II study

      CANCER
    14. Ferrari, AC; Chachoua, A; Singh, H; Rosenthal, M; Taneja, S; Bednar, M; Mandeli, J; Muggia, F
      A phase I/II study of weekly paclitaxel and 3 days of high dose oral estramustine in patients with hormone-refractory prostate carcinoma

      CANCER
    15. Pfeifer, BL; Pirani, JF; Hamann, SR; Klippel, KF
      PC-SPES, a dietary supplement for the treatment of hormone-refractory prostate cancer

      BJU INTERNATIONAL
    16. Haapala, K; Lehtimaki, T; Ilveskoski, E; Koivisto, PA
      Apolipoprotein E genotype is not linked to locally recurrent hormone-refractory prostate cancer

      PROSTATE CANCER AND PROSTATIC DISEASES
    17. Nupponen, NN; Visakorpi, T
      Molecular cytogenetics of prostate cancer

      MICROSCOPY RESEARCH AND TECHNIQUE
    18. Orlando, M; Chacon, M; Salum, G; Chacon, DR
      Low-dose continuous oral fosfestrol is highly active in 'hormone-refractory' prostate cancer

      ANNALS OF ONCOLOGY
    19. Sumiyoshi, Y; Hashine, K; Nakatsuzi, H; Yamashita, Y; Karashima, T
      Oral estramustine phosphate and oral etoposide for the treatment of hormone-refractory prostate cancer

      INTERNATIONAL JOURNAL OF UROLOGY
    20. Ather, MH; Abbas, F
      Prognostic significance of neuroendocrine differentiation in prostate cancer

      EUROPEAN UROLOGY
    21. Sella, A; Flex, D; Konichezky, M; Sulkes, A; Baniel, J
      Combination chemotherapy following adrenal suppression in androgen-independent prostate cancer

      EUROPEAN UROLOGY
    22. Leung, SYL; Jackson, J; Miyake, H; Burt, H; Gleave, ME
      Polymeric micellar paclitaxel phosphorylates Bcl-2 and induces apoptotic regression of androgen-independent LNCaP prostate tumors

      PROSTATE
    23. Hautmann, S; Huland, E; Wullbrand, A; Friedrich, M; Huland, H
      Treatment of metastatic hormone-refractory prostate adenocarcinoma (MatLyLu) in Copenhagen rats with micro-osmotic interleukin-2 pumps

      ANTICANCER RESEARCH
    24. Kalkner, KM; Westlin, JE; Strang, P
      (89)strontinm in the management of painful sceletal metastases

      ANTICANCER RESEARCH
    25. Mucci, NR; Akdas, G; Manely, S; Rubin, MA
      Neuroendocrine expression in metastatic prostate cancer: Evaluation of high throughput tissue microarrays to detect heterogeneous protein expression

      HUMAN PATHOLOGY
    26. Nishiyama, T; Terunuma, M
      Hormonal sensitivity following endocrine withdrawal in hormone-refractory prostate cancer

      UROLOGIA INTERNATIONALIS
    27. Small, EJ; Reese, DM
      New treatment strategies in advanced prostate cancer

      RADIOLOGIC CLINICS OF NORTH AMERICA
    28. Odrazka, K; Vanasek, J; Vaculikova, M; Stejskal, J; Filip, S
      The role of chemotherapy in prostate cancer

      NEOPLASMA
    29. Trivedi, C; Redman, B; Flaherty, LE; Kucuk, O; Du, W; Heilbrun, LK; Hussain, M
      Weekly 1-hour infusion of paclitaxel - Clinical feasibility and efficacy in patients with hormone-refractory prostate carcinoma

      CANCER
    30. Nishimura, K; Nonomura, N; Yasunaga, Y; Takaha, N; Inoue, H; Sugao, H; Yamaguchi, S; Ukimura, O; Miki, T; Okuyama, A
      Low doses of oral dexamethasone for hormone-refractory prostate carcinoma

      CANCER
    31. Bracarda, S; Tonato, M; Rosi, P; De Angelis, V; Mearini, E; Cesaroni, S; Fornetti, P; Porena, M
      Oral estramustine and cyclophosphamide in patients with metastatic hormonerefractory prostate carcinoma - A phase II study

      CANCER
    32. Dawson, NA; Conaway, M; Halabi, S; Winer, EP; Small, EJ; Lake, D; Vogelzang, NJ
      A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma - Cancer and leukemia group B study 9181

      CANCER
    33. Saif, MW; Figg, WD; Hewitt, S; Brosky, K; Reed, E; Dahut, W
      Malignant ascites as only manifestation of metastatic prostate cancer

      PROSTATE CANCER AND PROSTATIC DISEASES
    34. Sakamoto, N; Eto, M; Ando, S
      Surgical excision of a metastatic adrenal lesion in a patient with prostatic cancer

      INTERNATIONAL JOURNAL OF UROLOGY
    35. Lara, PN; Meyers, FJ
      Treatment options in androgen-independent prostate cancer

      CANCER INVESTIGATION
    36. Nupponen, N; Visakorpi, T
      Molecular biology of progression of prostate cancer

      EUROPEAN UROLOGY
    37. Huan, SD; Stewart, DJ; Aitken, SE; Segal, R; Yau, JC
      Combination of epirubicin and cisplatin in hormone-refractory metastatic prostate cancer

      AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
    38. Drachenberg, DE; Elgamal, AAA; Rowbotham, R; Peterson, M; Murphy, GP
      Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer

      PROSTATE
    39. Murphy, GP; Tjoa, BA; Simmons, SJ; Jarisch, J; Bowes, VA; Ragde, H; Rogers, M; Elgamal, A; Kenny, GM; Cobb, OE; Ireton, RC; Troychak, MJ; Salgaller, ML; Boynton, AL
      Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: A phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease

      PROSTATE
    40. Sinha, AA; Quast, BJ; Reddy, PK; Elson, MK; Wilson, MJ
      Intravenous injection of an immunoconjugate (anti-PSA-IgG conjugated to 5-fluoro-2 '-deoxyuridine) selectively inhibits cell proliferation and induces cell death in human prostate cancer cell tumors grown in nude mice

      ANTICANCER RESEARCH
    41. Kim, J; Logothetis, CJ
      Serologic tumor markers, clinical biology, and therapy of prostatic carcinoma

      UROLOGIC CLINICS OF NORTH AMERICA
    42. Beedassy, A; Cardi, G
      Chemotherapy in advanced prostate cancer

      SEMINARS IN ONCOLOGY
    43. Millikan, RE
      Chemotherapy of advanced prostatic carcinoma

      SEMINARS IN ONCOLOGY
    44. Kamradt, JM; Pienta, KJ
      Novel molecular targets for prostate cancer therapy

      SEMINARS IN ONCOLOGY
    45. Senderowicz, AM; Reid, R; Headlee, D; Abornathy, T; Horti, J; Lush, RM; Reed, E; Figg, WD; Sausville, EA
      A phase II trial of gallium nitrate in patients with androgen-metastatic prostate cancer

      UROLOGIA INTERNATIONALIS
    46. Ehara, H; Yang, M; Kawamura, T; Deguchi, T; Kawada, Y; Shimokawa, K; Tanaka, T
      Loss of tissue immunoreactive androgen receptor in prostate cancer presenting initially as an intracranial tumor

      UROLOGIA INTERNATIONALIS
    47. Arah, IH; Dixon, SC; Horti, J; Figg, WD
      Enhanced activity of estramustine, vinblastine, etoposide, and suramin in prostate carcinoma

      NEOPLASMA
    48. Koivisto, PA; Helin, HJ
      Androgen receptor gene amplification increases tissue PSA protein expression in hormone-refractory prostate carcinoma

      JOURNAL OF PATHOLOGY
    49. Falcone, A; Antonuzzo, A; Danesi, R; Allegrini, G; Monica, L; Pfanner, E; Masi, G; Ricci, S; Del Tacca, M; Conte, P
      Suramin in combination with weekly epirubicin for patients with advanced hormone-refractory prostate carcinoma

      CANCER
    50. HORTI J; FIGG WD; WEINBERGER B; KOHLER D; SARTOR O
      A PHASE-II STUDY OF BROMOCRIPTINE IN PATIENTS WITH ANDROGEN-INDEPENDENT PROSTATE-CANCER

      Oncology Reports
    51. JUNGI WF; BERNHARD J; HURNY C; SCHMITZ SFH; HANSELMANN S; GUSSET H; PESTALOZZI D; GOLDHIRSCH A
      EFFECT OF CARBOPLATIN ON RESPONSE AND PALLIATION IN HORMONE-REFRACTORY PROSTATE-CANCER

      Supportive care in cancer
    52. DOWLING AJ; TANNOCK IF
      SYSTEMIC TREATMENT FOR PROSTATE-CANCER

      Cancer treatment reviews
    53. SHINOHARA N; DEMURA T; MATSUMURA K; TOYODA K; KASHIWAGI A; NAGAMORI S; OHMURO H; OHZONO S; KOYANAGI T
      5-FLUOROURACIL AND LOW-DOSE RECOMBINANT INTERFERON-ALPHA-2A IN PATIENTS WITH HORMONE-REFRACTORY ADENOCARCINOMA OF THE PROSTATE

      The Prostate
    54. KALKNER KM; WESTLIN JE; NILSSON S; STRANG P
      PAIN FIGURES ARE UNSUITABLE FOR THE DETERMINATION OF PALLIATIVE RADIOTHERAPY PORTALS IN PATIENTS WITH HORMONE-REFRACTORY PROSTATIC-CANCER

      Anticancer research
    55. KALKNER KM; NILSSON S; WESTLIN JE
      [IN-111-DTPA-D-PHE(1)]-OCTREOTIDE SCINTIGRAPHY IN PATIENTS WITH HORMONE-REFRACTORY PROSTATIC ADENOCARCINOMA CAN PREDICT THERAPY OUTCOME WITH OCTREOTIDE TREATMENT - A PILOT-STUDY

      Anticancer research
    56. Pilat, MJP; Kamradt, JM; Pienta, KJ
      Hormone resistance in prostate cancer

      CANCER AND METASTASIS REVIEWS
    57. Bui, M; Reiter, RE
      Stem cell genes in androgen-independent prostate cancer

      CANCER AND METASTASIS REVIEWS
    58. Craft, N; Sawyers, CL
      Mechanistic concepts in androgen-dependence of prostate cancer

      CANCER AND METASTASIS REVIEWS
    59. EDELMAN MJ; MEYERS FJ; GRENNAN T; LAUDER J; DOROSHOW J
      PHASE-II TRIAL OF PYRAZINE DIAZOHYDROXIDE IN ANDROGEN-INDEPENDENT PROSTATE-CANCER

      Investigational new drugs
    60. Rajagopalan, K; Peereboom, D; Budd, GT; Olencki, T; Murthy, S; Elson, P; McLain, D; Bukowski, R
      Phase II trial of circadian infusion floxuridine (FUDR) in hormone refractory metastatic prostate cancer

      INVESTIGATIONAL NEW DRUGS
    61. KOIVISTO P
      ANEUPLOIDY AND RAPID CELL-PROLIFERATION IN RECURRENT PROSTATE CANCERSWITH ANDROGEN RECEPTOR GENE AMPLIFICATION

      PROSTATE CANCER AND PROSTATIC DISEASES
    62. KALKNER KM; GINMAN C; NILSSON S; BERGSTROM M; ANTONI G; AHLSTROM H; LANGSTROM B; WESTLIN JE
      POSITRON EMISSION TOMOGRAPHY (PET) WITH C-11 5-HYDROXYTRYPTOPHAN (5-HTP) IN PATIENTS WITH METASTATIC HORMONE-REFRACTORY PROSTATIC ADENOCARCINOMA

      Nuclear medicine and biology
    63. RAGHAVAN D; KOCZWARA B; JAVLE M
      EVOLVING STRATEGIES OF CYTOTOXIC CHEMOTHERAPY FOR ADVANCED PROSTATE-CANCER

      European journal of cancer
    64. WATANABE M; USHIJIMA T; SHIRAISHI T; YATANI R; SHIMAZAKI J; KOTAKE T; SUGIMURA T; NAGAO M
      GENETIC ALTERATIONS OF ANDROGEN RECEPTOR GENE IN JAPANESE HUMAN PROSTATE-CANCER

      Japanese Journal of Clinical Oncology
    65. DIXON SC; ZALLES A; GIORDANO C; LUSH RM; VENZON D; REED E; FIGG WD
      IN-VITRO EFFECT OF GALLIUM NITRATE WHEN COMBINED WITH KETOCONAZOLE INTHE PROSTATE-CANCER CELL-LINE PC-3

      Cancer letters
    66. MIGLIETTA L; CANOBBIO L; GRANETTO C; VANNOZZI MO; ESPOSITO M; BOCCARDO F
      SURAMIN EPIDOXORUBICIN ASSOCIATION IN HORMONE-REFRACTORY PROSTATE-CANCER - PRELIMINARY-RESULTS OF A PILOT PHASE-II STUDY/

      Journal of cancer research and clinical oncology
    67. KOIVISTO P; VISAKORPI T; RANTALA I; ISOLA J
      INCREASED CELL-PROLIFERATION ACTIVITY AND DECREASED CELL-DEATH ARE ASSOCIATED WITH THE EMERGENCE OF HORMONE-REFRACTORY RECURRENT PROSTATE-CANCER

      Journal of pathology
    68. SMALL EJ; BARON A; BOK R
      SIMULTANEOUS ANTIANDROGEN WITHDRAWAL AND TREATMENT WITH KETOCONAZOLE AND HYDROCORTISONE IN PATIENTS WITH ADVANCED PROSTATE CARCINOMA

      Cancer
    69. FIGG WD; KROOG G; DURAY P; WALTHER MM; PATRONAS N; SARTOR O; REED E
      FLUTAMIDE WITHDRAWAL PLUS HYDROCORTISONE RESULTED IN CLINICAL COMPLETE RESPONSE IN A PATIENT WITH PROSTATE CARCINOMA

      Cancer
    70. POMER S; KALBLE T
      TOPICAL APPROACHES IN GENE-THERAPY IN CAR CINOMA OF PROSTATE - NOW SUFFICIENTLY WELL-TRIED FOR CLINICAL USE

      Aktuelle Urologie
    71. OTTO T; REMBRINK K; GOEPEL M; KREGE S; MEYERSCHWICKERATH M; RUBBEN H
      TREATMENT OF HORMONE-REFRACTORY CARCINOMA OF THE PROSTATE WITH MITOXANTRONE

      Der Urologe
    72. NEWLING DWW
      THE MANAGEMENT OF HORMONE-REFRACTORY PROSTATE-CANCER

      European urology
    73. MAFFEZZINI M; SIMONATO A; FORTIS C
      SALVAGE IMMUNOTHERAPY WITH SUBCUTANEOUS RECOMBINANT INTERLEUKIN-2 (RIL-2) AND ALPHA-INTERFERON (A-IFN) FOR STAGE D3 PROSTATE CARCINOMA FAILING 2ND-LINE HORMONAL TREATMENT

      The Prostate
    74. KOIVISTO P; VISAKORPI T; KALLIONIEMI OP
      ANDROGEN RECEPTOR GENE AMPLIFICATION - A NOVEL MOLECULAR MECHANISM FOR ENDOCRINE THERAPY RESISTANCE IN HUMAN PROSTATE-CANCER

      Scandinavian journal of clinical & laboratory investigation
    75. MAULARDDURDUX C; DUFOUR B; HENNEQUIN C; CHRETIEN Y; DELANIAN S; HOUSSET M
      PHASE-II STUDY OF THE ORAL CYCLOPHOSPHAMIDE AND ORAL ETOPOSIDE COMBINATION IN HORMONE-REFRACTORY PROSTATE CARCINOMA PATIENTS

      Cancer
    76. SCHER HI; MAZUMDAR M; KELLY WK
      CLINICAL-TRIALS IN RELAPSED PROSTATE-CANCER - DEFINING THE TARGET

      Journal of the National Cancer Institute
    77. LANKFORD SP; POLLACK A; ZAGARS GK
      RADIOTHERAPY FOR REGIONALLY LOCALIZED HORMONE-REFRACTORY PROSTATE-CANCER

      International journal of radiation oncology, biology, physics
    78. MAULARD C; RICHAUD P; DROZ JP; JESSUELD D; DUFOURESQUERRE F; HOUSSET M
      PHASE I-II STUDY OF THE SOMATOSTATIN ANALOG LANREOTIDE IN HORMONE-REFRACTORY PROSTATE-CANCER

      Cancer chemotherapy and pharmacology
    79. NAITO S; UEDA T; KOTOH S; KUMAZAWA J; ITOH K; SAGIYAMA K; OMOTO T; ANDOH S; HASEGAWA Y; FUJISAWA Y
      TREATMENT OF ADVANCED HORMONE-REFRACTORY PROSTATE CARCINOMA WITH A COMBINATION OF ETOPOSIDE, PIRARUBICIN AND CISPLATIN

      Cancer chemotherapy and pharmacology
    80. FIGG WD; THIBAULT A; COOPER MR; REID R; HEADLEE D; DAWSON N; KOHLER DR; REED E; SARTOR O
      A PHASE-I STUDY OF THE SOMATOSTATIN ANALOG SOMATULINE IN PATIENTS WITH METASTATIC HORMONE-REFRACTORY PROSTATE-CANCER

      Cancer
    81. PIENTA KJ; REDMAN BG; HUSSAIN M; ESPER PS; FLAHERTY LE
      INHIBITION OF PROSTATE-CANCER GROWTH BY ESTRAMUSTINE AND ETOPOSIDE

      Cancer
    82. HUAN SD; AITKEN SE; STEWART DJ
      5-FLUOROURACIL AND HIGH-DOSE FOLINIC ACID IN HORMONE-REFRACTORY METASTATIC PROSTATE-CANCER - A PHASE-II STUDY

      Annals of oncology
    83. NAIK H; LEHR J; AKHTAR A; PIENTA K
      ORAL CYCLOPHOSPHAMIDE AND ORAL HYDROXYUREA IN THE TREATMENT OF HORMONE-REFRACTORY PROSTATE-CANCER IN RATS

      Anticancer research
    84. QUILTY PM; KIRK D; BOLGER JJ; DEARNALEY DP; LEWINGTON VJ; MASON MD; REED NSE; RUSSELL JM; YARDLEY J
      A COMPARISON OF THE PALLIATIVE EFFECTS OF SR-89 AND EXTERNAL-BEAM RADIOTHERAPY IN METASTATIC PROSTATE-CANCER

      Radiotherapy and oncology
    85. BANG YJ; PIRNIA F; FANG WG; KANG WK; SARTOR O; WHITESELL L; HA MJ; TSOKOS M; SHEAHAN MD; NGUYEN P; NIKLINSKI WT; MYERS CE; TREPEL JB
      TERMINAL NEUROENDOCRINE DIFFERENTIATION OF HUMAN PROSTATE CARCINOMA-CELLS IN RESPONSE TO INCREASED INTRACELLULAR CYCLIC-AMP

      Proceedings of the National Academy of Sciences of the United Statesof America
    86. HUSSAIN MH; PIENTA KJ; REDMAN BG; CUMMINGS GD; FLAHERTY LE
      ORAL ETOPOSIDE IN THE TREATMENT OF HORMONE-REFRACTORY PROSTATE-CANCER

      Cancer
    87. KANTOFF PW; BLOCK C; LETVAK L; GEORGE M
      14-DAY CONTINUOUS-INFUSION OF MITOXANTRONE IN HORMONE-REFRACTORY METASTATIC ADENOCARCINOMA OF THE PROSTATE

      American journal of clinical oncology
    88. ROTH BJ; YEAP BY; WILDING G; KASIMIS B; MCLEOD D; LOEHRER PJ
      TAXOL IN ADVANCED, HORMONE-REFRACTORY CARCINOMA OF THE PROSTATE - A PHASE-II TRIAL OF THE EASTERN-COOPERATIVE-ONCOLOGY-GROUP

      Cancer


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 28/05/20 alle ore 21:45:47